Smith Shellnut Wilson LLC ADV lessened its holdings in Celgene Corporation (NASDAQ:CELG) by 4.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,071 shares of the biopharmaceutical company’s stock after selling 158 shares during the period. Smith Shellnut Wilson LLC ADV’s holdings in Celgene Corporation were worth $303,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. State Street Corp raised its stake in Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the period. Bank of New York Mellon Corp raised its stake in Celgene Corporation by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after acquiring an additional 472,067 shares during the period. American Century Companies Inc. raised its stake in Celgene Corporation by 4.4% in the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after acquiring an additional 276,089 shares during the period. Pioneer Investment Management Inc. raised its stake in Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after acquiring an additional 710,584 shares during the period. Finally, Clearbridge Investments LLC raised its stake in Celgene Corporation by 24.1% in the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares during the period. Institutional investors and hedge funds own 79.33% of the company’s stock.

In other news, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James J. Loughlin sold 18,500 shares of the stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $133.57, for a total value of $2,471,045.00. Following the transaction, the director now owns 32,877 shares in the company, valued at $4,391,380.89. The disclosure for this sale can be found here. Insiders have sold a total of 63,006 shares of company stock worth $8,490,806 over the last quarter. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Sold by Smith Shellnut Wilson LLC ADV” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.watchlistnews.com/celgene-corporation-celg-shares-sold-by-smith-shellnut-wilson-llc-adv/1578547.html.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 0.14% during mid-day trading on Thursday, hitting $144.04. The stock had a trading volume of 1,261,445 shares. The stock has a market cap of $112.69 billion, a P/E ratio of 44.61 and a beta of 1.89. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $144.59. The firm has a 50 day moving average price of $135.45 and a 200-day moving average price of $127.81.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.44 EPS. On average, equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

A number of research firms recently weighed in on CELG. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and increased their price target for the company from $96.93 to $131.70 in a research note on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target on the stock in a research note on Thursday, August 10th. SunTrust Banks, Inc. set a $150.00 price target on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 6th. Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 27th. Finally, William Blair restated an “outperform” rating on shares of Celgene Corporation in a research note on Monday, June 26th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $149.34.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.